Results 31 to 40 of about 21,171,014 (388)

A brief haemophilia pain coping questionnaire [PDF]

, 2008
Development and psychometric assessment of a questionnaire measuring pain coping for people with haemophiliaPain coping strategies are important influences on outcomes among people with painful chronic conditions. The pain coping strategies questionnaire
Anie, Barry, Dozois, Elander, Gil, Hastie, Hays, Hays, Hill, Jensen, Kerns, Lawson, McCracken, Riley, Riley, Robinson, Rosenstiel, Santavirta, Swartzman, Tan, Tuttle   +20 more
core   +2 more sources

Treatment of a patient with severe haemophilia A presenting with left extra pleural haematoma and diagnosed with inhibitors – case report

The Journal of Haemophilia Practice, 2022
Haemophilia is an inherited X-linked bleeding disorder characterised by a deficiency or absence of clotting factor VIII (haemophilia A) or IX (haemophilia B), which can cause musculoskeletal bleeding. The standard treatment for haemophilia is with factor
Das Arijit, Dutta Anupam, BBV Ramanan, Sreeraj Sanchu TK   +3 more
doaj   +1 more source

Successful elimination of factor VIII inhibitor using cyclosporin A [PDF]

, 2003
No abstract ...
Dykes, Gordon D. O. Lowe, Grunewald, Hay, Isobel D. Walker, Lian, Mark D. McColl, Morrison, Peter S. Maclean, Pfliegler, R. Campbell Tait   +10 more
core   +1 more source

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study

Haemophilia, 2020
Persons with haemophilia A (PwHA) with factor (F)VIII inhibitors, including children, have impaired health‐related quality of life (HRQoL). The HAVEN 2 study (NCT027955767) of paediatric PwHA with FVIII inhibitors demonstrated that subcutaneous ...
M. Mancuso, J. Mahlangu, R. Sidonio, P. Trask, Marianne Uguen, Tiffany Y. Chang, M. Shima, G. Young, J. Oldenburg, S. von Mackensen   +9 more
semanticscholar   +1 more source

Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]

, 2017
The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo, Liumbruno, Giancarlo Maria, Marano, Giuseppe, Mengoli, Carlo, Piccinini, Vanessa, Pupella, Simonetta, Vaglio, Stefania   +6 more
core   +1 more source

Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study

Haemophilia, 2020
The prevalence of arthropathy in moderate haemophilia A (MHA) and B (MHB) is not well known.
Ragnhild J Måseide, E. Berntorp, J. Astermark, Anna Olsson, M. Bruzelius, T. Frisk, V. Nummi, R. Lassila, G. Tjønnfjord, P. Holme   +9 more
semanticscholar   +1 more source

Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study

Orphanet Journal of Rare Diseases, 2022
Background Haemophilia bears substantial humanistic and economic burden on children and their caregivers. Characterising the differential impact of severe versus moderate paediatric haemophilia is important for clinical and health policy decisions.
Idaira Rodriguez-Santana, Pronabesh DasMahapatra, Tom Burke, Zalmai Hakimi, José Bartelt-Hofer, Jameel Nazir, Jamie O’Hara   +6 more
doaj   +1 more source

Haemophilia item bank based on International Classification of Functioning, Disability and Health: a systematic review

Hematology, 2023
Background and Objectives Haemophilia comprises a continuum of blood disorders that often include joint and muscular dysfunction, which may lead to a constellation of activity limitations and participation restrictions.
Bao-Feng Geng, Chun Feng, Shou-Guo Liu, Zhong-Li Jiang, Feng Lin   +4 more
doaj   +1 more source

Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

Haemophilia, 2020
Standard treatment of haemophilia A is based on replacing the missing coagulation factor VIII (FVIII) to treat and prevent bleeding episodes. The most challenging complication of FVIII therapy is the development of neutralizing antibodies (inhibitors ...
C. Escuriola-Ettingshausen, G. Auerswald, C. Königs, K. Kurnik, U. Scholz, R. Klamroth, J. Oldenburg   +6 more
semanticscholar   +1 more source

International consensus recommendations on the management of people with haemophilia B

Therapeutic Advances in Hematology, 2022
Haemophilia B is a rare X-linked genetic deficiency of coagulation factor IX (FIX) that, if untreated, can cause recurrent and disabling bleeding, potentially leading to severe arthropathy and/or life-threatening haemorrhage.
Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d’Oiron, Cédric Hermans, Victor Jiménez-Yuste, Adriana Linares, Tadashi Matsushita, Simon McRae, Margareth C. Ozelo, Sean Platton, Darrel Stafford, Robert F. Sidonio, Andreas Tiede   +14 more
doaj   +1 more source